logo

ARENA PHAR(NSDQ:ARNA)
Arena Pharmaceuticals, Inc. a biotechnology company that has developed CART, a new technology which they use to identify new drug candidates more efficiently than traditional drug discovery techniques. Using CART, they have discovered new drug candidates in the areas of obesity and schizophrenia. Based on the success using CART, they have established collaborative drug discovery programs with a number of pharmaceutical and biotechnology companies.
# Employees: 499
Address: 6166 Nancy Ridge Drive,San Diego,CA,USA
Phone: 858 453-7200
Fax: 858 453-7210
Website: www.arenapharm.com
Email: invest@arenapharm.com
Sector: Medical
Industry: MED-BIOMED/GENE
Executive Officers
Jack Lief (Presi.; C.E.O.; Dir.)
Robert E. Hoffman (V.P.; Fin.; Chief Acctg. Off.; C.F.O.)
Donald D. Belcher (Dir.)
Scott H. Bice (Dir.)
Dominic P. Behan Ph.D (Dir.,)
Dividend
Ex-Dividend Date: N/A
Annual Dividend: N/A
Current Dividend Yield: N/A
Dividend Paid (3 months): N/A
Indicated Dividend: N/A
Earnings
Last Earnings Date: 9/30/2009
Next Earnings Date(Expected): 3/11/2010
Mean EPS (Next Qtr): ($0.31)
Mean EPS (Year): ($1.80)
Mean Estimate(Long Term): $17.50
P/E Ratio(Based on EPS estimate): -0.010
Number of Estimates: 14
Shares Performance
Period ARNA Compare to S&P
YTD -15.83 % -30.34 %
4 Weeks -19.12 % -20.00 %
12 Weeks -25.32 % -29.59 %
Shares Information
Analyst Coverage: Y
Avg Volume: 2978122
Shares Outstanding: 92M
Market Cap: $0.33B
52 Week High: $7.15
52 Week Low: $2.32
P/E Ratio: -0.010
PEG Ratio: -0.010
Split: On 1/1/1990 ARNA split by factor of 0.070
Earnings Performance
EPS Growth in Last Quarter: 20.83 %
EPS Growth in Last Year: 50.00 %
Sales Growth in Last Quarter: 7.87 %
Sales Growth in Last Quarter: 41.03 %
Financials
Qtr Book Value: $6.25
Cash Flow/Share: ($0.01)
Change in Payout Ratio: -0.010
Price/Sales: 31.250
Fundamental data is provided by Zacks Investment Research, market data is provided by AlphaTrade. , and Commentary and Press Releases provided by Quotemedia